Macrophage Activation Syndrome

Hematology/Oncology Clinics of North America

Volumn 29, Issue 5, 2015, Pages 927-941

  Ravelli, Angelo ^a   Davì, Sergio ^b   Minoia, Francesca ^b   Martini, Alberto ^a   Cron, Randy Q ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c CHILDREN S HOSPITAL OF ALABAMA   (United States)

Author keywords

Hemophagocytic lymphohistiocytosis; Hemophagocytic syndrome; Interleukin 1 inhibitors; Macrophage activation syndrome; Proinflammatory cytokines; Systemic juvenile idiopathic arthritis

Indexed keywords

CYCLOPHOSPHAMIDE; ETANERCEPT; ETOPOSIDE; IMMUNOGLOBULIN; THYMOCYTE ANTIBODY; TOCILIZUMAB;

CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG RESPONSE; HISTOPATHOLOGY; HUMAN; LABORATORY DIAGNOSIS; MACROPHAGE ACTIVATION SYNDROME; MANAGED CARE; NONHUMAN; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT OUTCOME; DISEASE MANAGEMENT;

DISEASE MANAGEMENT; HUMANS; MACROPHAGE ACTIVATION SYNDROME; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 84942370294     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2015.06.010     Document Type: Review

References (77)

1. Ravelli A., Martini A. Macrophage activation syndrome. Pediatric rheumatology 2008, 55-63. Elsevier, Amsterdam. T.H. Lehman, R. Cimaz (Eds.).
2. Grom A.A. Macrophage activation syndrome. Textbook of pediatric rheumatology 2010, 674-681. Saunders Elsevier, Philadelphia. 6th edition. J. Cassidy, R.E. Petty (Eds.).
3. Bae C.B., Jung J.Y., Kim H.A., et al. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features, predictive factors, and prognosis in 21 patients. Medicine (Baltimore) 2015, 94(4):e451.
4. Parodi A., Davi S., Pringe A.B., et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum 2009, 60(11):3388-3399.
5. Lambotte O., Khellaf M., Harmouche H., et al. Characteristic and long-term outcome of 15 episodes of systemic lupus erythematosus-associated hemophagocytic syndrome. Medicine (Baltimore) 2006, 85(3):169-182.
6. Simonini G., Pagnini I., Innocenti L., et al. Macrophage activation syndrome/hemophagocytic lymphohistiocytosis and Kawasaki disease. Pediatr Blood Cancer 2010, 55(3):592.
7. Rigante D., De Rosa G., Bertoni B., et al. Large pericardial effusion requiring pericardiocentesis as cardinal sign of macrophage activation syndrome in systemic onset-juvenile idiopathic arthritis. Rheumatol Int 2007, 27(8):767-770.
8. Rossi-Semerano L., Hermeziu B., Fabre M., et al. Macrophage activation syndrome revealing familial Mediterranean fever. Arthritis Care Res (Hoboken) 2011, 63(5):780-783.
9. Hadchouel M., Prieur A.M., Griscelli C. Acute hemorrhagic, hepatic and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr 1985, 106:562-566.
10. Stephan J.L., Zeller J., Hubert P., et al. Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol 1993, 11(4):451-456.
11. Ramanan A.V., Schneider R. Macrophage activation syndrome-what's in a name!. J Rheumatol 2003, 30:2513-2516.
12. Filipovich A.H. Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology Am Soc Hematol Educ Program 2009, 127-131.
13. Favara B.E., Feller A.C., Pauli M., et al. Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol 1997, 29(3):157-166.
14. Behrens E.M., Beukelman T., Paessler M., et al. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007, 34(5):1133-1138.
15. Bleesing J., Prada A., Siegel D.M., et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007, 56(3):965-971.
16. Minoia F., Davi S., Horne A., et al. Clinical features, treatment and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A multinational, multicenter study of 362 patients. Arthritis Rheumatol 2014, 66(11):3160-3169.
17. Minoia F., Davì S., Horne A., et al. Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Rheumatol 2015, 42(6):994-1001.
18. Schulert G.S., Grom A.A. Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies. Annu Rev Med 2015, 66:145-159.
19. Weaver L.K., Behrens E.M. Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis. Curr Opin Rheumatol 2014, 26(5):562-569.
20. Ravelli A., Grom A.A., Behrens E.M., et al. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012, 13(4):289-298.
21. Henter J.I., Horne A., Arico M., et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007, 48(2):124-131.
22. Sullivan K.E., Delaat C.A., Douglas S.D., et al. Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives. Pediatr Res 1998, 44(4):465-468.
23. Stepp S.E., Dufourcq-Lagelouse R., Deist F.L., et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999, 286(5446):1957-1959.
24. Feldmann J., Callebaut I., Raposo G., et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 2003, 115(4):461-473.
25. Zur S.U., Rohr J., Seifert W., et al. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. Am J Hum Genet 2009, 85(4):482-492.
26. Zur S.U., Schmidt S., Kasper B., et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet 2005, 14(6):827-834.
27. Janka G., Zur S.U. Familial and acquired hemophagocytic lymphohistiocytosis. Hematology Am Soc Hematol Educ Program 2005, 82-88.
28. Jenkins M.R., Rudd-Schmidt J.A., Lopez J.A., et al. Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J Exp Med 2015, 212(3):307-317.
29. Grom A.A., Mellins E.D. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol 2010, 22(5):561-566.
30. Grom A.A. Natural killer cell dysfunction: A common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis?. Arthritis Rheum 2004, 50(3):689-698.
31. Grom A.A., Villanueva J., Lee S., et al. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 2003, 142(3):292-296.
32. Vastert S.J., van W.R., D'Urbano L.E., et al. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 2010, 49(3):441-449.
33. Villanueva J., Lee S., Giannini E.H., et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005, 7(1):R30-R37.
34. Hazen M.M., Woodward A.L., Hofmann I., et al. Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum 2008, 58(2):567-570.
35. Zhang M., Behrens E.M., Atkinson T.P., et al. Genetic defects in cytolysis in macrophage activation syndrome. Curr Rheumatol Rep 2014, 16(9):439.
36. Spessott W.A., Sanmillan M.L., McCormick M.E., et al. Hemophagocytic lymphohistiocytosis caused by dominant-negative mutations in STXBP2 that inhibit SNARE-mediated membrane fusion. Blood 2015, 125(10):1566-1577.
37. Yanagimachi M., Goto H., Miyamae T., et al. Association of IRF5 polymorphisms with susceptibility to hemophagocytic lymphohistiocytosis in children. J Clin Immunol 2011, 31(6):946-951.
38. Kaufman K.M., Linghu B., Szustakowski J.D., et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol 2014, 66(12):3486-3495.
39. Behrens E.M., Canna S.W., Slade K., et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest 2011, 121(6):2264-2277.
40. Jordan M.B., Hildeman D., Kappler J., et al. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 2004, 104(3):735-743.
41. Billiau A.D., Roskams T., Van Damme-Lombaerts R., et al. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-a-producing macrophages. Blood 2005, 105(4):1648-1651.
42. Maeno N., Takei S., Nomura Y., et al. Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima, et al. Arthritis Rheum 2002, 46(9):2539-2541.
43. Mazodier K., Marin V., Novick D., et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 2005, 106(10):3483-3489.
44. Kimura Y., Weiss J.E., Haroldson K.L., et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2013, 65(5):745-752.
45. Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol 2002, 14(5):548-552.
46. Gorelik M., Fall N., Altaye M., et al. Follistatin-like protein 1 and the ferritin/erythrocyte sedimentation rate ratio are potential biomarkers for dysregulated gene expression and macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2013, 40(7):1191-1199.
47. Gorelik M., Torok K.S., Kietz D.A., et al. Hypocomplementemia associated with macrophage activation syndrome in systemic juvenile idiopathic arthritis and adult onset Still's disease: 3 cases. J Rheumatol 2011, 38(2):396-397.
48. Lehmberg K., Pink I., Eulenburg C., et al. Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis. J Pediatr 2013, 162(6):1245-1251.
49. Kelly A., Ramanan A.V. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr Opin Rheumatol 2007, 19(5):477-481.
50. Ruperto N., Brunner H.I., Quartier P., et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012, 367(25):2396-2406.
51. De Benedetti F., Brunner H.I., Ruperto N., et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012, 367(25):2385-2395.
52. De Kleer I.M., Brinkman D.M., Ferster A., et al. Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity. Ann Rheum Dis 2004, 63(10):1318-1326.
53. Buoncompagni A., Loy A., Sala I., et al. The paradox of macrophage activation syndrome triggered by biologic medications. Pediatr Rheumatol Online J 2005, 3:70-73.
54. Nigrovic P.A., Mannion M., Prince F.H., et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011, 63(2):545-555.
55. Arico M., Janka G., Fischer A., et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia 1996, 10(2):197-203.
56. Ho C., Yao X., Tian L., et al. Marrow assessment for hemophagocytic lymphohistiocytosis demonstrates poor correlation with disease probability. Am J Clin Pathol 2014, 141:62-71.
57. Davì S., Lattanzi B., Demirkaya E., et al. Toward the development of new diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Paediatr Rheumatol 2012, 1:1-7.
58. Pelkonen P., Swanljung K., Siimes M.A. Ferritinemia as an indicator of systemic disease activity in children with systemic juvenile rheumatoid arthritis. Acta Paediatr Scand 1986, 75(1):64-68.
59. Davi S., Minoia F., Pistorio A., et al. Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Arthritis Rheumatol 2014, 66(10):2871-2880.
60. Davi S., Consolaro A., Guseinova D., et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2011, 38(4):764-768.
61. Mouy R., Stephan J.L., Pillet P., et al. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr 1996, 129(5):750-754.
62. Ravelli A., De Benedetti F., Viola S., et al. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr 1996, 128(2):275-278.
63. Prahalad S., Bove K.E., Dickens D., et al. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol 2001, 28(9):2120-2124.
64. Ramanan A.V., Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 2003, 30(2):401-403.
65. Miettunen P.M., Narendran A., Jayanthan A., et al. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) 2011, 50(2):417-419.
66. Bruck N., Suttorp M., Kabus M., et al. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol 2011, 17(1):23-27.
67. Kelly A., Ramanan A.V. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 2008, 4(11):615-620.
68. Lurati A., Teruzzi B., Salmaso A., et al. Macrophage activation syndrome (MAS) during anti-IL1 therapy (anakinra) in a patient affected by systemic juvenile arthritis (soJIA): a report and review of the literature. Pediatr Rheumatol Online J 2005, 3:79-85.
69. Zeft A., Hollister R., LaFleur B., et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol 2009, 15(4):161-164.
70. Yokota S., Imagawa T., Mori M., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008, 371(9617):998-1006.
71. Kobayashi M., Takahashi Y., Yamashita H., et al. Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol 2011, 21(1):92-96.
72. Record J.L., Beukelman T., Cron R.Q. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J Rheumatol 2011, 38(1):180-181.
73. Coca A., Bundy K.W., Marston B., et al. Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin. Clin Immunol 2009, 132(1):10-18.
74. Mahlaoui N., Ouachee-Chardin M., de Saint B.G., et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics 2007, 120(3):e622-e628.
75. Alexeeva E.I., Valieva S.I., Bzarova T.M., et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol 2011, 30(9):1163-1172.
76. Balamuth N.J., Nichols K.E., Paessler M., et al. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol 2007, 29(8):569-573.
77. Bosman G., Langemeijer S.M., Hebeda K.M., et al. The role of rituximab in a case of EBV-related lymphoproliferative disease presenting with haemophagocytosis. Neth J Med 2009, 67(8):364-365.